Results 231 to 240 of about 901,705 (329)

Safety and Efficacy of the NMDA‐2b‐Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Selective N‐methyl‐D‐aspartate receptor subunit 2b negative allosteric modulators (NR2B NAMs) are being explored as potential new treatment options for major depressive disorder (MDD). This Phase Ib, randomized, double‐blind, placebo‐controlled, parallel‐group trial was conducted in adults (N = 59) with moderate‐to‐severe MDD and insufficient response ...
Roger S. McIntyre   +9 more
wiley   +1 more source

Results of the ACCOuNT Trial: A Multi‐Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Pharmacogenomics implementation efforts have increased over the last decade, but no published prospective pharmacogenomics trials have formally evaluated utility in underrepresented populations. We present final results from the ACCOuNT trial, a multi‐institutional prospective study [NCT03225820] in which African American inpatients were genotyped and ...
Zhong Huang   +17 more
wiley   +1 more source

UGT1A1 and Sacituzumab Govitecan Toxicity: A Systematic Review and Meta‐Analysis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Sacituzumab govitecan (SG), a humanized antibody‐drug conjugate, enables intra‐tumor delivery of SN‐38, the active metabolite of irinotecan, with the aim of increasing efficacy. SN‐38 is predominantly inactivated by the polymorphically expressed uridine diphosphate glucuronosyltransferase 1A1 (UGT1AA) where reduced activity can lead to toxicity.
Cinzia Dello Russo   +4 more
wiley   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich   +5 more
wiley   +1 more source

Investigating Factors for an Inclusive Workforce for Women in the Logistics and Supply Chain Industry

open access: yesCorporate Social Responsibility and Environmental Management, EarlyView.
ABSTRACT This study seeks to identify and analyze the major factors that contribute to an inclusive workforce for women in the area of logistics and supply chain. It further addresses the need for gender diversity and inclusivity in a traditionally male‐dominated field by adopting a human‐centric approach.
Vernika Agarwal   +4 more
wiley   +1 more source

Memory words - in memorium. [PDF]

open access: yesInt J Circumpolar Health
Kallenborn R   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy